MTOR F2108L

CI-VAR-00001092Explore in graph →ENST00000361445.4:c.6324C>ACIViC 470

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm1
MTOR F2108L	Sirolimus	Predictive	D	Supports Resistance	4	accepted	EID1543 MCF-7 breast cancer cell line was exposed to mTOR inhibitors AZD8055 or rapamycin until resistance developed. Deep sequencing revealed an MTOR F2108L mutation in rapamycin-resistant clones (RR2 cells)… (full text at CIViC) PMID 27279227 · Rodrik-Outmezguine et al., 2016 · Open in CIViC	civic
Thyroid Gland Anaplastic Carcinoma1
MTOR F2108L	Everolimus	Predictive	C	Supports Resistance	5	accepted	EID1110 After an 18-month sustained response to everolimus (in a patient with metastatic anaplastic thyroid carcinoma whose pretreatment tumor harbored a TSC2 Q1178* inactivating mutation, see EID1108), the r… (full text at CIViC) PMID ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.